Use of big data in drug development for precision medicine.
Use of big data in drug development for precision medicine.
复制标题
DOI：
10.1080/23808993.2016.1174062
复制
发表时间：
2016
影响因子：
1.2
通讯作者：
Hoshida Y
中科院分区：
文献类型：
--
作者：
Kim RS;Goossens N;Hoshida Y
药物开发是一个昂贵而漫长的过程，成功率极低，缺乏对药物反应和毒性的个体多样性的考虑。在过去十年中，另一种“大数据”方法以前所未有的速度扩展，其基础是化学物质、疾病基因/蛋白质靶点、功能读数和涵盖个体间遗传变异和毒性的临床信息的电子数据库的开发。这种范式转变使得能够系统地、高通量地和加速地鉴定新药或针对每个个体患者中特异性存在的致病性分子畸变的现有药物的重新用途适应症。来自信息技术和直接面向消费者的基因检测行业的爆炸式兴趣进一步促进了大数据的使用，以实现个性化的精准医疗。在这里，我们概述了目前可用的资源，并讨论了未来的前景。
Drug development has been a costly and lengthy process with an extremely low success rate and lack of consideration of individual diversity in drug response and toxicity. Over the past decade, an alternative “big data” approach has been expanding at an unprecedented pace based on the development of electronic databases of chemical substances, disease gene/protein targets, functional readouts, and clinical information covering inter-individual genetic variations and toxicities. This paradigm shift has enabled systematic, high-throughput, and accelerated identification of novel drugs or repurposed indications of existing drugs for pathogenic molecular aberrations specifically present in each individual patient. The exploding interest from the information technology and direct-to-consumer genetic testing industries has been further facilitating the use of big data to achieve personalized Precision Medicine. Here we overview currently available resources and discuss future prospects.